Investment Rating - The industry investment rating is maintained at "Overweight" [7] Core Insights - The report highlights the continuous upgrading of policies in the Heilongjiang biomanufacturing industry, focusing on innovative traditional Chinese medicine and innovative medical devices [4] - The report emphasizes the significant revisions to the Drug Administration Law, which provides institutional support for pharmaceutical innovation and high-quality development [4] - The report identifies three major transformations in China's innovative drug business development (BD) in 2026: technology output combined with product authorization, platform cooperation, and global parallel innovation [8] Summary by Sections Industry Performance - Over the past 12 months, the industry has shown a relative return of -7.06% compared to the CSI 300 index, with an absolute return of 11.53% [3] Investment Highlights - The report notes that BD transactions in the pharmaceutical sector are focused on unmet clinical needs, technological differentiation, and global value [6] - Key areas of focus include oncology therapies such as dual antibodies, ADCs, and TCE combinations, with significant financial agreements highlighted, such as a $650 million upfront payment for a PD-1/VEGF dual antibody [6] - The metabolic disease sector is centered on long-acting GLP-1 and small nucleic acid precision therapies, with notable collaborations resulting in substantial upfront payments and potential total amounts [6] Company-Specific Developments - Companies like Andover Pharmaceuticals and Frontier Biotech have secured significant collaborations with major pharmaceutical firms, indicating a trend towards platform-based cooperation and technology output [7] - Specific collaborations include a $1.05 billion deal for a CTLA-4 inhibitor and a $400 million agreement for small nucleic acid drugs, showcasing the growing interest in innovative therapies [7] - The report suggests monitoring companies such as Rebio Biotech and WuXi AppTec for their advancements in small nucleic acids and platform capabilities [8]

CONSHOHOCKEN, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 2:30 P.M. ET. The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events page. A replay of the webcast will be available after the event. About Madrigal PharmaceuticalsMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharm ...

Key Takeaways MDGL posted a Q4 loss of $2.57 per share as operating expenses surged sharply.Rezdiffra sales drove $321.1M in Q4 revenues, beating estimates on strong demand.Madrigal ended 2025 with $958.4M in sales as phase III studies advance toward full approval.Madrigal Pharmaceuticals (MDGL) reported a fourth-quarter 2025 loss of $2.57 per share, in contrast to the Zacks Consensus Estimate of earnings of 4 cents. The large difference is mainly due to a significant rise in operating expenses. In the same ...

Stock of Madrigal Pharmaceuticals, Inc. (MDGL) is falling about 11 percent on Thursday morning trading despite reporting positive fourth quarter financial results, which saw a drop in net loss to $58.58 million, or $2.57 per share, from $59.42 million, or $2.71 per share, last year.The company's stock is currently trading at $436.13, down 11.33 percent or $55.71, over the previous close of $491.49 on the Nasdaq. It has traded between $265.00 and $615.00 in the past one year.The company's revenue for the qu ...

Madrigal (MDGL) came out with a quarterly loss of $2.57 per share versus the Zacks Consensus Estimate of $0.04. This compares to a loss of $2.71 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -7,442.86%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $1.98 per share when it actually produced a loss of $5.08, delivering a surprise of -156.57%.Over the last four quarters, the company has ...

Financial Performance - The company has an accumulated deficit of $2,090.5 million as of December 31, 2025, and has incurred losses since inception [422]. - Product revenue for the year ended December 31, 2025, was $958.4 million, a 432% increase from $180.1 million in 2024, driven by increased demand for Rezdiffra and a full year of commercialization [448]. - Cost of sales for 2025 was $56.1 million, up 801% from $6.2 million in 2024, reflecting the same factors as product revenue [449]. - Research and development expenses increased to $388.5 million in 2025, a 64% rise from $236.7 million in 2024, primarily due to business development transactions [450]. - Selling, general and administrative expenses rose to $813.8 million in 2025, an 87% increase from $435.1 million in 2024, mainly due to increased commercial activities for Rezdiffra [451]. - Interest income decreased to $37.4 million in 2025 from $46.7 million in 2024, primarily due to higher principal balances and interest rates [452]. - Interest expense increased to $22.3 million in 2025, up 52% from $14.7 million in 2024, due to a higher average outstanding principal balance [453]. - For the year ended December 31, 2025, net cash used in operating activities was $189.6 million, primarily due to losses from operations [475]. - The company reported net cash provided by financing activities of $735.1 million for the year ended December 31, 2024, mainly from the 2024 Offering [480]. Product Development and Commercialization - Rezdiffra, the company's medication for MASH, was approved by the FDA in March 2024 and began generating revenue in April 2024 [419]. - The company launched Rezdiffra in Germany in September 2025, marking it as the first medication approved for noncirrhotic MASH with moderate to advanced liver fibrosis [419]. - The company plans to evaluate additional therapies to expand the eligible patient population for Rezdiffra [423]. - The company expects fluctuations in financial results based on net sales of Rezdiffra and the progress of research and development efforts [423]. - The company has acquired rights to several new drug candidates, including MGL-2086 and ervogastat, to enhance its pipeline for MASH treatment [420]. - The company received FDA approval for Rezdiffra in March 2024 and EC approval in August 2025, with a tiered royalty payable to Roche on net sales [484]. - In July 2025, the company entered into a license agreement with CSPC for MGL-2086, paying an upfront fee of $120.0 million and potential milestone payments of up to $2.0 billion [485]. Operational Expenses and Future Outlook - The company expects to incur additional operating losses due to planned expenditures for commercializing Rezdiffra and expanding operations in Europe [422]. - Research and development expenses are expected to remain substantial as the company conducts clinical trials and manufacturing studies [429]. - Selling, general and administrative expenses are anticipated to increase as the company expands its operations and commercialization efforts [433]. - The company anticipates continued losses until sufficient revenue is generated from Rezdiffra and other future products, with potential future capital needs for operations [457]. Financing and Cash Position - As of December 31, 2025, cash, cash equivalents, restricted cash, and marketable securities totaled $988.6 million, compared to $931.3 million in 2024 [455]. - The company entered into a Financing Agreement on July 17, 2025, providing up to $500.0 million in senior secured credit facilities [462]. - As of December 31, 2025, the outstanding principal under the Financing Agreement was $350.0 million, with an interest rate of 8.75% [467]. - The company has approximately $268.3 million in obligations related to agreements for active pharmaceutical ingredients as of December 31, 2025 [488]. - The company has not entered into any hedging arrangements for foreign currency risk as it expands operations into Europe [492]. - Inflation has not materially affected the company's financial condition or results of operations during the years ended December 31, 2025, 2024, or 2023 [494]. Public Offerings - In March 2024, the company completed a public offering, selling 750,000 shares at $260.00 per share and pre-funded warrants for 1,557,692 shares at $259.9999 each, raising approximately $659.9 million in net proceeds [468][469]. - The 2023 public offering closed on October 3, 2023, with gross proceeds of $500.0 million and net proceeds of approximately $472.0 million after expenses [471][472].

Madrigal Pharmaceuticals (NasdaqGS:MDGL) Q4 2025 Earnings call February 19, 2026 08:00 AM ET Company ParticipantsBill Sibold - CEODavid Soergel - CMOMardi Dier - CFOTina Ventura - Chief Investor Relations OfficerYasmeen Rahimi - 5-star analyst and MdConference Call ParticipantsAlex Thompson - AnalystEllie Merle - Senior Biotech Equity Research AnalystJay Olson - Md and Senior Biotechnology AnalystJonathan Wolleben - Md and Senior Research AnalystManoj Garg - AnalystMichael DiFiore - Equity Research AnalystP ...

Madrigal Pharmaceuticals (NasdaqGS:MDGL) Q4 2025 Earnings call February 19, 2026 08:00 AM ET Company ParticipantsBill Sibold - CEODavid Soergel - CMOMardi Dier - CFOTina Ventura - Chief Investor Relations OfficerYasmeen Rahimi - 5-star analyst and MdConference Call ParticipantsAlex Thompson - AnalystEllie Merle - Senior Biotech Equity Research AnalystJay Olson - Md and Senior Biotechnology AnalystJonathan Wolleben - Md and Senior Research AnalystManoj Garg - AnalystMichael DiFiore - Equity Research AnalystP ...

Madrigal Pharmaceuticals (NasdaqGS:MDGL) Q4 2025 Earnings call February 19, 2026 08:00 AM ET Speaker10Good morning, and thank you for standing by. Welcome to Madrigal Pharmaceuticals' fourth quarter and full year 2025 earnings conference call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. As a reminder, today's conference call is being recorded. I would now like to introduce Ms. Tina Ventura, Chief Investor Relations ...

4Q25 Financial Results Feb. 19, 2026 NASDAQ: MDGL © 2026 Madrigal Pharmaceuticals, Inc. All rights reserved. Forward-looking Statements This presentation includes "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, that are based on Madrigal's beliefs and assumptions and on information currently available to it but are subject to factors beyond its control. Forward-looking statements reflect management's current knowledge, assumpt ...